Background People with cancer are known to be at increased risk of venous
thromboembolism (VTE), and this risk is believed to vary according to cancer type, stage of …

Purpose Patients with cancer are increasingly at risk for venous thromboembolism (VTE).
Rates of VTE, however, vary markedly among patients with cancer. Design This review …

Background—Long-term low-molecular-weight heparin (LMWH) is the current standard for
treatment of venous thromboembolism (VTE) in cancer patients. Whether treatment …

Abstract Objectives Venous thrombotic events (VTEs) are a frequent complication of non-
small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune …

Cancer patients are well-known to be at increased risk of venous thromboembolism (VTE).
However, the risk varies widely between patients and over the natural history of malignancy …

Background Patients with lung cancer are at increased risk for venous thromboembolism
(VTE), particularly those receiving chemotherapy. It is estimated that 8% to 15% of patients …

BACKGROUND: The incidence and economic impact of lung cancer-associated venous
thromboembolic (VTE) events in a contemporary ambulatory setting is unknown. PATIENTS …

Background Patients with cancer are at increased risk for venous thromboembolism (VTE),
and 8% to 15% of patients with advanced non–small-cell lung cancer (NSCLC) experience …

Venous thromboembolism (VTE) is a common complication of malignancies and
epidemiological studies suggest that lung cancer belonged to the group of malignancies …

Background: Venous thromboembolism (VTE) is a potentially preventable cause of death in
people with lung cancer. Identification of those most at risk and high-risk periods may …